Platform & Strategy

The company will pursue a multi-dimensional strategic focus based on the development of multiple oxygen-based therapies; strategic patenting and patent acquisitions; as well as excellence in research and clinical development.
Our primary goals include:

  • - Making OXYCYTE the first oxygen carrier for traumatic brain injury and sickle-cell crisis
  • - Developing a multiple-product portfolio
  • - Achieving profitability through licensing
  • - Seeking access to major capital markets









 

 

 

 

  • Funds breathe new life into Oxygen Biotherapeutics

By DAVID RANII
Posted on Wednesday, Jan. 25, 2012

After a tumultuous year that featured the dismissal of its CEO, drug-development company Oxygen Biotherapeutics is starting 2012 in its best financial shape in years.
The small, publicly traded Morrisville company turned a financial corner at the end of last year when it sold $7.5 million in preferred stock and warrants to institutional investors. The company received $3.5 million in December, with the second installment expected midyear.

In the past, Oxygen Bio has raised money that would carry it forward for about six months, but this was a richer deal. More...

Quick Links